Immunome, Inc.
IMNM
Rank in Stocks
#5487
Immunome, Inc., a biotechnology company, engages in the discovery, design,... Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Share Price
$19.36
Last synced: 2026-11-09
Market Cap
$2.28B
Change (1 day)
3.47%
Change (1 year)
10.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Immunome, Inc. (IMNM)
Category
Healthcare
Operating Margin for Immunome, Inc. (IMNM)
Operating Margin as of November 2026 TTM: 0.00%
According to Immunome, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -3,084.76%.
Operating Margin history for Immunome, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -3,084.76% | -8.80% |
| 2024 | -3,382.37% | 332.89% |
| 2023 | -781.35% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Immunome, Inc.'s operating margin
What was Immunome, Inc.'s operating margin in 2025?
In 2025, Immunome, Inc.'s operating margin was -3,084.76%, compared with -3,382.37% in 2024.
How has Immunome, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Immunome, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2024 (-3,382.37%).
How does Immunome, Inc.'s operating margin compare with similar companies?
Immunome, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.